# RAS Quantification in Patients With Aliskiren or Candesartan

> **NCT01827202** · PHASE4 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 24 (actual)

## Conditions studied

- Hypertension
- Chronic Kidney Disease
- Proteinuria

## Interventions

- **OTHER:** RAS blockade discontinuation
- **DRUG:** Aliskiren
- **DRUG:** Candesartan

## Key facts

- **NCT ID:** NCT01827202
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827202, "RAS Quantification in Patients With Aliskiren or Candesartan". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01827202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*